MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Greil, Richard [1 ,2 ]
Kopeckova, Katerina [3 ,4 ]
Arcaini, Luca [5 ,6 ]
Amin, Aasim [7 ]
de Graaf, Katrien [8 ]
Jegg, Anna-Maria [7 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] Salzburg Canc Res Inst Ctr Clin Canc & Immunol Tr, Canc Cluster, Salzburg, Austria
[3] Charles Univ Prague, Fac Med 2, Dept Oncol, Prague, Czech Republic
[4] Motol Univ Hosp, Prague, Czech Republic
[5] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy
[6] Univ Pavia, Dept Mol Med, Pavia, Italy
[7] MorphoSys AG, Clin Dev, Planegg, Germany
[8] MorphoSys AG, Clin Pharmacol, Planegg, Germany
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
ABCL; CD19; tafasitamab; lenalidomide; DLBCL; MINDway; Trial-in-Progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-052
引用
收藏
页码：S356 / S356
页数：1
相关论文
共 50 条
  • [41] Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab plus Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Nowakowski, Grzegorz
    Yoon, Dok Hyun
    Joffe, Erel
    Zinzani, Pier Luigi
    Sabatelli, Lorenzo
    Waltl, Eva E.
    Alvero, Carmelita G.
    Hess, Georg
    Riedell, Peter
    Kim, Kibum
    Brixner, Diana
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S359 - S359
  • [42] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [43] RE-MIND: Comparing Tafasitamab plus Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Zinzani, Pier Luigi
    Rodgers, Thomas
    Marino, Dario
    Frezzato, Maurizio
    Barbui, Anna Maria
    Castellino, Claudia
    Meli, Erika
    Fowler, Nathan H.
    Salles, Gilles
    Feinberg, Bruce
    Kurukulasuriya, Nuwan C.
    Tillmanns, Sascha
    Parche, Stephan
    Dey, Debarshi
    Fingerle-Rowson, Gunter
    Ambarkhane, Sumeet
    Winderlich, Mark
    Nowakowski, Grzegorz S.
    CLINICAL CANCER RESEARCH, 2021, 27 (22) : 6124 - 6134
  • [44] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
  • [45] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [46] Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma
    Randall, Michael P.
    Rauschecker, Andreas
    Gima-Lange, Liam
    Wilmoth, Jenai
    Chen, Lingjing
    Lu, Ming
    Geng, Huimin
    Abdulhaq, Haifaa
    Rubenstein, James L.
    BLOOD, 2023, 142
  • [47] Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
    Pirosa, Maria Cristina
    Stathis, Anastasios
    Zucca, Emanuele
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [48] A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward, Jeffrey P.
    Thein, Jessica
    Luo, Jingqin
    Wagner-Johnston, Nina D.
    Cashen, Amanda F.
    Fehniger, Todd A.
    Bartlett, Nancy L.
    BLOOD, 2015, 126 (23)
  • [49] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Crombie, Jennifer L.
    Kim, Austin I.
    Bartlett, Nancy L.
    Redd, Robert A.
    Patterson, Victoria
    Carey, Celeste
    Balasubramanian, Sobana
    Odejide, Oreofe O.
    Merryman, Reid W.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Fisher, David C.
    Herrera, Alex F.
    Davids, Matthew S.
    Shipp, Margaret A.
    Armand, Philippe
    Shouse, Geoffrey P.
    BLOOD, 2023, 142
  • [50] Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Maddocks, Kami J.
    Duell, Johannes
    Gonzalez-Barca, Eva
    Jurczak, Wojciech
    Liberati, Anna Marina
    de Vos, Sven
    Nagy, Zsolt
    Obr, Ales
    Gaidano, Gianluca
    Abrisqueta, Pau
    Andre, Marc
    Dreyling, Martin
    Menne, Tobias F.
    Dirnberger-Hertweck, Maren
    Weirather, Johannes
    Ambarkhane, Sumeet
    Salles, Gilles
    BLOOD, 2020, 136
12345